Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

10x Genomics (TXG) Net Cash Flow (2018 - 2025)

Historic Net Cash Flow for 10x Genomics (TXG) over the last 8 years, with Q4 2025 value amounting to $41.2 million.

  • 10x Genomics' Net Cash Flow rose 17657.32% to $41.2 million in Q4 2025 from the same period last year, while for Dec 2025 it was $129.4 million, marking a year-over-year increase of 95972.9%. This contributed to the annual value of $129.4 million for FY2025, which is 95972.9% up from last year.
  • As of Q4 2025, 10x Genomics' Net Cash Flow stood at $41.2 million, which was up 17657.32% from $35.0 million recorded in Q3 2025.
  • 10x Genomics' Net Cash Flow's 5-year high stood at $112.4 million during Q1 2023, with a 5-year trough of -$275.9 million in Q1 2022.
  • Its 5-year average for Net Cash Flow is -$10.8 million, with a median of -$6.2 million in 2023.
  • In the last 5 years, 10x Genomics' Net Cash Flow tumbled by 90358.27% in 2022 and then soared by 105166.43% in 2025.
  • Over the past 5 years, 10x Genomics' Net Cash Flow (Quarter) stood at -$12.9 million in 2021, then decreased by 11.91% to -$14.4 million in 2022, then surged by 407.79% to $44.5 million in 2023, then tumbled by 221.03% to -$53.8 million in 2024, then skyrocketed by 176.57% to $41.2 million in 2025.
  • Its Net Cash Flow stands at $41.2 million for Q4 2025, versus $35.0 million for Q3 2025 and $20.3 million for Q2 2025.